JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB261831

Human ADRB1 (beta 1 Adrenergic Receptor) knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

ADRB1 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 11 bp deletion in exon 1 and 1 bp insertion in exon 1. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
2 Images
Sanger Sequencing - Human ADRB1 (beta 1 Adrenergic Receptor) knockout HeLa cell line (AB261831)
  • Sanger seq

Unknown

Sanger Sequencing - Human ADRB1 (beta 1 Adrenergic Receptor) knockout HeLa cell line (AB261831)

Allele-2 : 1 bp insertion in exon 1.

Sanger Sequencing - Human ADRB1 (beta 1 Adrenergic Receptor) knockout HeLa cell line (AB261831)
  • Sanger seq

Unknown

Sanger Sequencing - Human ADRB1 (beta 1 Adrenergic Receptor) knockout HeLa cell line (AB261831)

Allele-1 : 11 bp deletion in exon 1.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 11 bp deletion in exon 1 and 1 bp insertion in exon 1

Antibiotic resistance

Puromycin 1µg/mL

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab261831-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab261831 Human ADRB1 (beta 1 Adrenergic Receptor) knockout HeLa cell line", "number":"AB261831-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB261831-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab261831-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB261831-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab261831 Human ADRB1 (beta 1 Adrenergic Receptor) knockout HeLa cell line", "number":"AB261831-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab261831-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab261831 Human ADRB1 (beta 1 Adrenergic Receptor) knockout HeLa cell line", "number":"AB261831-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab261831-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab261831 Human ADRB1 (beta 1 Adrenergic Receptor) knockout HeLa cell line", "number":"AB261831-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
ADRB1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The beta 1 adrenergic receptor also known as beta-1 adrenoceptor or beta-1 receptor is a G protein-coupled receptor involved in the response to epinephrine and norepinephrine. It has a molecular mass of approximately 51 kDa. This receptor is mainly expressed in the heart where it plays a significant role in regulating cardiovascular functions. It is also found in other tissues like the brain and kidneys though at lower levels. The beta-1 adrenergic receptor functions by activating adenylate cyclase which increases intracellular cAMP levels.
Biological function summary

The beta 1 adrenergic receptor influences heart rate and cardiac contractility. This receptor is key in the sympathetic nervous system affecting physiological responses during stress or exercise. It does not form part of a complex in its active state. Upon activation the receptor enhances cardiac output by increasing the force and frequency of heart contractions. It also contributes to the relaxation of vascular and smooth muscle tissues facilitating better blood flow and pressure regulation.

Pathways

Beta 1 adrenergic receptor is integral to the adrenergic signaling pathway. It works alongside proteins like adenylate cyclase to modulate the levels of cAMP within the cell which acts as a secondary messenger in signal transduction. The receptor plays a significant role in the fight-or-flight response coordinating with other adrenergic receptors like the beta 2 adrenergic receptor to ensure a well-rounded physiological reaction to stressors. Another pathway of significance is the cardiac beta-adrenergic signaling which involves the regulation of heart muscle activities.

The beta 1 adrenergic receptor is associated with heart failure and hypertension. In heart failure altered expression or function of this receptor can lead to impaired contractile response and cardiac performance. In hypertension overactive adrenergic receptor signaling contributes to increased cardiac output and blood pressure. Related proteins include the beta-2 adrenergic receptor and angiotensin II which can exacerbate these conditions when dysregulated influencing the development and progression of cardiovascular diseases. Esmolol a beta-1 selective blocker is often used to manage these conditions by targeting the receptor specifically to reduce heart rate and blood pressure.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com